Qube Research & Technologies (QRT)
VTGN icon

Qube Research & Technologies (QRT)’s VistaGen Therapeutics VTGN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-60,139
Closed -$39.8K – 4192
2025
Q4 		$39.8K Buy
+60,139
New +$217K ﹤0.01% 3308
2024
Q3 		– Sell
-492
Closed -$1.71K – 4181
2024
Q2 		$1.71K Buy
+492
New +$2.13K ﹤0.01% 3201
2023
Q4 		– Sell
-1,192
Closed -$6.25K – 4778
2023
Q3 		$6.25K Buy
+1,192
New +$5.29K ﹤0.01% 3406

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Qube Research & Technologies (QRT)'s VTGN Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of VistaGen Therapeutics (VTGN) in Q1 2026, closing a stake of 60,139 shares — an estimated $39.8K sold.

Qube Research & Technologies (QRT) first reported a position in VTGN in Q3 2023 and held it in 3 quarters. The position peaked at $39.8K in Q4 2025. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Qube Research & Technologies (QRT) reported no remaining VistaGen Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 60,139 VistaGen Therapeutics shares in Q1 2026, an estimated $39.8K.
  • Qube Research & Technologies (QRT) first reported a position in VistaGen Therapeutics in Q3 2023 and held it in 3 quarters.
  • Qube Research & Technologies (QRT)'s VistaGen Therapeutics position peaked at $39.8K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.